Demand has never been greater for revolutionary technologies that deliver fast, inexpensive and accurate genome information. This challenge has catalysed the development of next-generation sequencing (NGS) technologies. The inexpensive production of large volumes of sequence data is the primary advantage over conventional methods. There are companies, which do the research in next generations sequencing. There is an increase in number of companies too. Companies which do research and production in next generation sequencing, are more focused on minimizing the mutations and minimize the genetic disorders.